Press coverage about uniQure N.V. (NASDAQ:QURE) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. uniQure N.V. earned a coverage optimism score of 0.19 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 46.9011709668573 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
A number of research firms have issued reports on QURE. Zacks Investment Research downgraded shares of uniQure N.V. from a “buy” rating to a “hold” rating in a report on Friday, November 10th. Leerink Swann lifted their target price on uniQure N.V. from $19.00 to $26.00 in a research note on Tuesday, November 7th. Evercore ISI assumed coverage on uniQure N.V. in a research note on Tuesday, November 7th. They set an “outperform” rating and a $22.00 target price on the stock. ValuEngine cut uniQure N.V. from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Finally, Chardan Capital set a $13.00 target price on uniQure N.V. and gave the stock a “buy” rating in a research note on Sunday, July 23rd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $17.43.
Shares of uniQure N.V. (NASDAQ QURE) opened at $15.04 on Friday. uniQure N.V. has a 52-week low of $4.72 and a 52-week high of $21.35. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.64 and a current ratio of 3.64.
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
Receive News & Ratings for uniQure N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure N.V. and related companies with MarketBeat.com's FREE daily email newsletter.